As Congress continues consideration of legislation to address the complex and difficult issues around needed oversight of pharmaceutical compounding, America’s hospitals know that protecting patients is always job number one.
Community hospitals across the nation rely on compounded pharmaceutical products for a variety of reasons, such as to address the recent severe drug shortage and occasional lack of availability of critical pharmaceuticals, as well as to meet informed physician preferences for a particular medication formulation to treat a specific patient condition.
There is a clear role for appropriate federal oversight and a role for the State Boards of Pharmacy to ensure patient safety; and America’s hospitals want assurance that, when they buy pharmaceutical products for their patients, the products are safe and effective.
Congress can begin to improve patient safety by clearly defining “compounding.” Too often, the root of many of the issues with compounding is the variation in definitions and the concomitant assumptions made about regulating compounding entities – resulting in varied implementation of regulations in multiple settings. This is why standards need to be clear both at the federal and state level, and hand-offs from one level of government to the other must also be clear.
Inspections are also an important part of ensuring that appropriate manufacturing practices are being followed. Individuals with expertise in inspections, compounding techniques, and good manufacturing practices should be involved in the process of issuing any necessary sanctions and in determining the outcomes and consequences of an inspection.
Finally, the development of a notification system where adverse events or reviews by State Pharmacy Boards can be centrally reported in a searchable database will make critical information readily available. Such tools are key to ensuring patient safety.
Our patients will be well served by efforts in Congress to provide clear and essential oversight authority to the Food and Drug Administration (FDA) while preserving the ability of hospitals to perform necessary compounding of drugs for individual patients. America’s hospitals are committed to working to ensure the health and safety of the patients and families we serve.
Today’s hearing on reforming drug compounding regulatory framework is a positive step towards ensuring the protection of our patients.